MARTINSRIED/MUNICH, Germany, May 25 /PRNewswire-FirstCall/ --
Princeton, N.J. -- GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX
index; Nasdaq: GPCB) announced today that Donald Soltysiak was elected to
its Supervisory Board at the Company's Annual Shareholders Meeting held in
Munich earlier today. Mr. Soltysiak is succeeding Dr. Prabhavathi
Fernandes, whose term ended with today's Shareholders Meeting.
Bernd R. Seizinger, M.D., Ph.D., Chief Executive Officer said: "I would
like to express my heartfelt appreciation to Dr. Fernandes for her
important contributions over the last four years on GPC Biotech's
Supervisory Board. I am deeply grateful for her guidance and support during
a time of such significant change and growth for our Company."
"On behalf of the Supervisory Board, I would also like to warmly thank
Dr. Fernandes for her dedication and support during her tenure on the
Board," said Jurgen Drews, M.D., Chairman of the GPC Biotech Supervisory
Board. "As a successful entrepreneur and leader in the biopharmaceutical
industry, her insights have been extremely valuable."
Dr. Drews continued: "As GPC Biotech moves forward in the next phase of
its corporate development, it is with great delight that I welcome Don
Soltysiak on our Supervisory Board. He is a highly experienced senior
pharmaceutical sales executive who led several successful launches of
blockbuster oncology drugs, including Taxol and Paraplatin. His advice will
be invaluable as GPC Biotech prepares for the commercialization of its
first drug."
"I am excited to have the opportunity to join the GPC Biotech
Supervisory Board as the Company moves into its commercialization stage,"
said Donald Soltysiak. "I look forward to assisting the Company as it
advances."
Donald Soltysiak was at Bristol-Myers Squibb for more than 30 years,
serving for 16 years as Senior Vice President of Sales for the U.S.
oncology division. He was responsible for several successful product
launches of key oncology drugs, including Paraplatin(R) (carboplatin) and
Taxol(R) (paclitaxel). Upon his retirement in 2003, Bristol-Myers Squibb
created the Donald J. Soltysiak Sales Leadership Award, which is awarded
annually to an outstanding oncology sales manager. He is now a consultant
to the biopharmaceutical industry and has served as an advisor for several
major oncology product launches.
Dr. Jurgen Drews and Dr. Metin Colpan, whose terms also ended today,
were re-elected to the Supervisory Board. All other agenda items were also
adopted by today's Annual Shareholders Meeting. For more information about
the results, please visit the Investor Relations/Shareholders Meeting
section of the Company's Web site at http://www.gpc-biotech.com.
About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company focused
on discovering, developing and commercializing new anticancer drugs. GPC
Biotech's lead product candidate satraplatin is currently under review by
the U.S. FDA for hormone-refractory prostate cancer patients whose prior
chemotherapy has failed. Satraplatin was in-licensed from Spectrum
Pharmaceuticals, Inc. GPC Biotech is also developing a monoclonal antibody
with a novel mechanism-of-action against a variety of lymphoid tumors,
currently in Phase 1 clinical development, and has ongoing drug development
and discovery programs that leverage its expertise in kinase inhibitors.
GPC Biotech AG is headquartered in Martinsried/Munich (Germany), and has a
wholly owned U.S. subsidiary headquartered in Princeton, New Jersey. For
additional information, please visit GPC Biotech's Web site at
http://www.gpc-biotech.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of GPC Biotech AG,
including statements about the status of the FDA review process. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause
future results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by such
forward-looking statements. Actual results could differ materially
depending on a number of factors, and we caution investors not to place
undue reliance on the forward- looking statements contained in this press
release. In particular, there can be no guarantee that additional
information relating to the safety, efficacy or tolerability of satraplatin
may be discovered upon further analysis of data from the SPARC trial or
analysis of additional data from other ongoing clinical trials for
satraplatin. Furthermore, we cannot guarantee that satraplatin will be
approved for marketing in a timely manner, if at all, by regulatory
authorities nor that, if marketed, satraplatin will be a successful
commercial product. We direct you to GPC Biotech's Annual Report on Form
20-F for the fiscal year ended December 31, 2005 and other reports filed
with the U.S. Securities and Exchange Commission for additional details on
the important factors that may affect the future results, performance and
achievements of GPC Biotech. Forward-looking statements speak only as of
the date on which they are made and GPC Biotech undertakes no obligation to
update these forward-looking statements, even if new information becomes
available in the future.
Satraplatin has not yet been approved by the FDA in the U.S., the EMEA
in Europe or any other regulatory authority and no conclusions can or
should be drawn regarding its safety or effectiveness. Only the relevant
regulatory authorities can determine whether satraplatin is safe and
effective for the use(s) being investigated.
Taxol(R) (paclitaxel) is a registered trademark of Bristol-Myers Squibb
Company
Paraplatin(R) (carboplatin) is a registered trademark of Bristol-Myers
Squibb Company
SOURCE GPC Biotech
 back to top
Related links:
http://www.gpc-biotech.com
CONTACT:
Martin Braendle, Director, Investor Relations
& Corporate Communications, +49-0-89-8565-2693,
ir@gpc-biotech.com, In the U.S.: Laurie Doyle, Director, Investor
Relations & Corporate Communications, +1-609-524-5884,
usinvestors@gpc-biotech.com, both of GPC Biotech AG; In Europe:
Brian Hudspith of Maitland, +44-0-20-7379-5151,
bhudspith@maitland.co.uk; In the U.S.: David Schull of Russo
Partners, LLC, +1-212-845-4271, david.schull@russopartnersllc.com
|
